PD-L1 blockade: rejuvenating T cells in CLL

被引：5
|
作者：
Kater, Arnon P. [1 ]
van der Windt, Gerritje J. W. [1 ]
机构：
[1] Acad Med Ctr Amsterdam, Amsterdam, Netherlands
来源：
BLOOD | 2015年 / 126卷 / 02期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; IBRUTINIB; INHIBITOR; LYMPHOMA; ITK;
D O I：
10.1182/blood-2015-05-638338
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, there are 2 articles by McClanahan et al describing T-cell defects in murine chronic lymphocytic leukemia (CLL) in the context of aging which show that therapeutic targeting of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) signaling prevents immune dysfunction and leukemia development.(1,2)
引用
收藏
页码：126 / 128
页数：5
相关论文
共 50 条
  • [21] Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Nowicki, Theodore S.
    Hu-Lieskovan, Siwen
    Ribas, Antoni
    CANCER JOURNAL, 2018, 24 (01): : 47 - 53
  • [22] Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
    Tu, Jingyao
    Xu, Haoran
    Ma, Li
    Li, Chunya
    Qin, Wan
    Chen, Xinyi
    Yi, Ming
    Sun, Li
    Liu, Bo
    Yuan, Xianglin
    THERANOSTICS, 2022, 12 (02): : 747 - 766
  • [23] Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    Iwai, Y
    Ishida, M
    Tanaka, Y
    Okazaki, T
    Honjo, T
    Minato, N
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) : 12293 - 12297
  • [24] PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
    Ganbaatar, Otgontuya
    Konnai, Satoru
    Okagawa, Tomohiro
    Nojima, Yutaro
    Maekawa, Naoya
    Minato, Erina
    Kobayashi, Atsushi
    Ando, Ryo
    Sasaki, Nobuya
    Miyakoshi, Daisuke
    Ichii, Osamu
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    PLOS ONE, 2020, 15 (11):
  • [25] CD57+CD8+T cells and response to PD-1/PD-L1 blockade in patients with NSCLC
    Zhou, Jianya
    Sun, Wenjia
    Zeng, Xun
    Zheng, Jing
    Qu, Jingjing
    Jiang, Nan
    Zhou, Jianying
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    MODERN PATHOLOGY, 2015, 28 : 123A - 123A
  • [27] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
    Inoue, Yusuke
    Osman, Murat
    Suda, Takafumi
    Sugimura, Haruhiko
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S199 - S202
  • [28] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    LABORATORY INVESTIGATION, 2015, 95 : 123A - 123A
  • [29] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
  • [30] Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN- production via PD-1/PD-L1 blockade in bovine mycoplasmosis
    Goto, Shinya
    Konnai, Satoru
    Okagawa, Tomohiro
    Nishimori, Asami
    Maekawa, Naoya
    Gondaira, Satoshi
    Higuchi, Hidetoshi
    Koiwa, Masateru
    Tajima, Motoshi
    Kohara, Junko
    Ogasawara, Satoshi
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    IMMUNITY INFLAMMATION AND DISEASE, 2017, 5 (03) : 355 - 363
12345